Weight Watchers Narrows FY26 Outlook As Clinical Subscription Revenue Grows 48%
WW International (Weight Watchers) reported Q3 2026 revenue of $152.9M, down 11% YoY, but narrowed FY26 revenue guidance to $625M-$630M. Clinical subscription revenue grew 48% to $38M, accounting for 25% of total revenue. The company reported net income of $15.1M, up from a $57.5M loss in Q3 2025. Adjusted EBITDA increased 21% YoY to $51.7M. WW stock is trading at $11.57, down 4.69%.
How this was made
The 30-second read
Why it matters
The narrowed guidance may trigger short‑term selling pressure, but the strong clinical segment growth offers a potential catalyst for a rebound.
Market read
First report of WW's Q3 results and FY guidance change; material for traders watching consumer discretionary earnings.
What to watch
Cash position of $126M provides runway for marketing spend; upcoming product launches may improve future guidance.
Background
WW International (Weight Watchers) posted Q3 earnings, highlighted a 48% jump in clinical subscription revenue, and narrowed its FY2026 outlook.
Ticker impact
WW reported Q3 2026 results and narrowed its FY2026 revenue to $625‑$630M and Adjusted EBITDA to $110‑$115M.
likely pressure as the market prices in the lower revenue outlook
Revenue guidance was reduced despite a profit beat, and the stock is already down 4.7%.
Market effects
Weight Watchers' guidance may signal slower consumer discretionary spending on health‑and‑wellness subscriptions.
U.S. small‑cap consumer discretionary segment could see modest downside pressure.
Limited to WW; no broader macro impact.
Counterpoint
The profit beat and strong clinical subscription growth could support a bounce if the market overreacts to the modest guidance reduction.
Key entities
- ExecutiveStephen Bye
CEO of WW, discussed strategic priorities.
- ExecutiveFelicia DellaFortuna
CFO of WW, commented on financial performance.



